Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India

Pediatric Infectious Disease Journal

Volumn 32, Issue 5, 2013, Pages 509-516

  Amdekar, Yeshwant K ^a   Lalwani, Sanjay K ^b   Bavdekar, Ashish ^c   Balasubramanian, S ^d   Chhatwal, Jugesh ^e   Bhat, Swarna Rekha ^f   Verghese, Valsan Philip ^g   Tansey, Susan P ^h   Gadgil, Durga ⁱ   Jiang, Qin ⁱ   Pride, Michael ⁱ   Emini, Emilio A ⁱ   Gruber, William C ⁱ   Scott, Daniel A ⁱ  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^b Bharati Vidyapeeth's Medical College   (India)

^c KEM HOSPITAL   (India)

^d MEDICAL RESEARCH FOUNDATION   (India)

^e CHRISTIAN MEDICAL COLLEGE   (India)

^f ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^g CHRISTIAN MEDICAL COLLEGE   (India)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

ⁱ PFIZER INC   (United States)

Author keywords

Immunogenicity; Pediatric; Pneumococcal vaccine; Safety

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; BACTERIAL VACCINE; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BRONCHIOLITIS; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART ARREST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PHASE 3 CLINICAL TRIAL; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEROTYPE; TODDLER; TREATMENT DURATION; VACCINATION; VIRUS MYOCARDITIS;

EID: 85027920725     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827b478d     Document Type: Article

References (25)

1. O'Brien KL, Wolfson LJ, Watt JP, et al; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374:893-902.
2. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec. 2007;82:93-104.
3. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86:408-416.
4. Levine OS, Cherian T. Pneumococcal vaccination for Indian children. Indian Pediatr. 2007;44:491-496.
5. Black S, Shinefield H, Fireman B, et al. Efficacy safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
6. Eskola J, Kilpi T, Palmu A, et al; Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
7. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
8. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
9. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Lancet. 1999;353:1216-1221.
10. Lee NY, Song JH, Kim S, et al. Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis. 2001;32:1463-1469.
11. Kanungo R, Rajalakshmi B. Serotype distribution & antimicrobial resistance in Streptococcus pneumoniae causing invasive & other infections in south India. Indian J Med Res. 2001;114:127-132.
12. Yeh SH, Gurtman A, Hurley DC, et al; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-e505.
13. Vanderkooi OG, Scheifele DW, Girgenti D, et al; Canadian PCV13 Study Group. Safety and immunogenic ity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31:72-77.
14. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenic ity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017-1026.
15. Snape MD, Klinger CL, Daniels ED, et al. Immunogenic ity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80-e90.
16. Kieninger DM, Kueper K, Steul K, et al; 006 study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010; 28:4192-4203.
17. Huang LM, Lin TY, Juergens C. Immunogenic ity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine. 2012;30:2054-2059.
18. World Health Organization Expert Committee on Biological Standardization. 54th Report. Annex 2: Recommendations for the production and control of pneumococcal conjugate vaccines. Geneva, Switzerland: World Health Organization; 2005.
19. Bryant KA, Block SL, Baker SA, et al; PCV13 Infant Study Group. Safety and immunogenic ity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125:866-875.
20. Väkeväinen M, Eklund C, Eskola J, et al. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J Infect Dis. 2001;184:789-793.
21. Yu X, Gray B, Chang S, et al. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis. 1999;180:1569-1576.
22. Heidelberger M, Jann K, Jann B, et al. Relations between structures of three K polysaccharides of Escherichia coli and cross-reactivity in antipneumo-coccal sera. J Bacteriol. 1968;95:2415-2417.
23. Heidelberger M, Nimmich W Additional immunochemical relationships of capsular polysaccharides of Klebsiella and pneumococci. J Immunol. 1972;109:1137-1144.
24. Mathew JL. Universal pneumococcal vaccination for India. Indian Pediatr. 2008;45:160-161.
25. Mishra A, Mishra R. Universal pneumococcal vaccination in India: is it a priority? Indian Pediatr. 2008;45:161-162.